Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study
Dulaglutide is an effective Glucagon-like Peptide-1 (GLP-1) Receptor Agonist (RA) in optimizing weight and glycemic control in obese patients with Type 2 Diabetes Mellitus (T2DM). The study's objective was the real-world evaluation of the metabolic effect of Dulaglutide on weight and glycemic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-02-01
|
| Series: | Journal of Biological Research |
| Subjects: | |
| Online Access: | https://pagepressjournals.org/index.php/jbr/article/view/10643 |
| _version_ | 1828013876869857280 |
|---|---|
| author | Adel G. Mohammed Samih A. Odhaib |
| author_facet | Adel G. Mohammed Samih A. Odhaib |
| author_sort | Adel G. Mohammed |
| collection | DOAJ |
| description |
Dulaglutide is an effective Glucagon-like Peptide-1 (GLP-1) Receptor Agonist (RA) in optimizing weight and glycemic control in obese patients with Type 2 Diabetes Mellitus (T2DM). The study's objective was the real-world evaluation of the metabolic effect of Dulaglutide on weight and glycemic control in patients with T2DM from Southern Iraq. This study is a six-month observational prospective longitudinal evaluation of 185 obese individuals with T2DM. They were initiated on Dulaglutide as an add-on drug with Oral Antidiabetic (OAD) or insulin therapy. General characteristics of the patients, glycated hemoglobin (HbA1c), blood glucose, lipid profile, and side effects profile were evaluated at the enrollment and the end of the study. The enrolled 185 obese patients with T2DM, had a T2DM duration (2 -14 years) and initial HbA1c range (6 - 19.5%), with different treatment modalities, including insulin, OADs, or both. The study showed a significant reduction in weight, HbA1c, and serum cholesterol, with minimal hypoglycemic events in 5% of patients (n=9). The gastrointestinal side effects were mild to moderate and self-limited in >96% of patients (n=178), while they were so severe in 4% (n=7) and caused discontinuation of Dulaglutide. Therefore, the insulin regimen was either stopped (n=28), changed (n=7), or reduced (n=9). No change on oral medications was performed in 141 patients. In conclusion, Dulaglutide 1.5 mg administered once a week significantly reduced the weight, HbA1c, Self-Monitoring of Blood Glucose (SMBG), and cholesterol levels with minimal hypoglycemic risk.
|
| first_indexed | 2024-04-10T09:51:48Z |
| format | Article |
| id | doaj.art-3427e0c2a9e947fca6590ed9f0108aed |
| institution | Directory Open Access Journal |
| issn | 1826-8838 2284-0230 |
| language | English |
| last_indexed | 2024-04-10T09:51:48Z |
| publishDate | 2023-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Journal of Biological Research |
| spelling | doaj.art-3427e0c2a9e947fca6590ed9f0108aed2023-02-16T22:42:08ZengPAGEPress PublicationsJournal of Biological Research1826-88382284-02302023-02-0110.4081/jbr.2023.10643Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational studyAdel G. Mohammed0Samih A. Odhaib1Adult endocrinologist, Thi Qar Specialized Diabetes Endocrine and Metabolism Center (TDEMC), Thi Qar Health Directorate, Thi QarDiabetes, Endocrine and Metabolism Division, Department of Medicine, College of Medicine, University of Thi-Qar, Thi Qar Dulaglutide is an effective Glucagon-like Peptide-1 (GLP-1) Receptor Agonist (RA) in optimizing weight and glycemic control in obese patients with Type 2 Diabetes Mellitus (T2DM). The study's objective was the real-world evaluation of the metabolic effect of Dulaglutide on weight and glycemic control in patients with T2DM from Southern Iraq. This study is a six-month observational prospective longitudinal evaluation of 185 obese individuals with T2DM. They were initiated on Dulaglutide as an add-on drug with Oral Antidiabetic (OAD) or insulin therapy. General characteristics of the patients, glycated hemoglobin (HbA1c), blood glucose, lipid profile, and side effects profile were evaluated at the enrollment and the end of the study. The enrolled 185 obese patients with T2DM, had a T2DM duration (2 -14 years) and initial HbA1c range (6 - 19.5%), with different treatment modalities, including insulin, OADs, or both. The study showed a significant reduction in weight, HbA1c, and serum cholesterol, with minimal hypoglycemic events in 5% of patients (n=9). The gastrointestinal side effects were mild to moderate and self-limited in >96% of patients (n=178), while they were so severe in 4% (n=7) and caused discontinuation of Dulaglutide. Therefore, the insulin regimen was either stopped (n=28), changed (n=7), or reduced (n=9). No change on oral medications was performed in 141 patients. In conclusion, Dulaglutide 1.5 mg administered once a week significantly reduced the weight, HbA1c, Self-Monitoring of Blood Glucose (SMBG), and cholesterol levels with minimal hypoglycemic risk. https://pagepressjournals.org/index.php/jbr/article/view/10643Dulaglutideglycated hemoglobintype 2 diabetes mellitusweight |
| spellingShingle | Adel G. Mohammed Samih A. Odhaib Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study Journal of Biological Research Dulaglutide glycated hemoglobin type 2 diabetes mellitus weight |
| title | Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study |
| title_full | Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study |
| title_fullStr | Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study |
| title_full_unstemmed | Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study |
| title_short | Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study |
| title_sort | effect of dulaglutide injection on weight beyond glycemic control real world observational study |
| topic | Dulaglutide glycated hemoglobin type 2 diabetes mellitus weight |
| url | https://pagepressjournals.org/index.php/jbr/article/view/10643 |
| work_keys_str_mv | AT adelgmohammed effectofdulaglutideinjectiononweightbeyondglycemiccontrolrealworldobservationalstudy AT samihaodhaib effectofdulaglutideinjectiononweightbeyondglycemiccontrolrealworldobservationalstudy |